Exabis Library
Welcome to the e-CCO Library!
P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P407: Thiopurines: use them or lose them? Results of an international survey
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P408: Are pharmacokinetics more unfavourable in inflammatory bowel disease patients aged over 60 years?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P408: Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P408: Intestinal failure in Crohn’s disease: A case–control study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in Norway
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P409: FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P409: Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM